MedTrace Logo

Effects of 5HTP on the Injured Human Spinal Cord

NCT04520178 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-27

No results posted yet for this study

Summary

This study will assess how the serotonin precursor, 5-HTP, alter nervous system excitability and motor function in individuals with spinal cord injuries of differing chronicity and severity. Participants will visit the lab on 4 separate occasions where they will be administered four different drugs in a randomized, double-blinded, placebo-controlled crossover design.

Conditions

  • Spinal Cord Injuries

Interventions

DRUG

5-Hydroxytryptophan 100 MG

100mg combined with 50mg carbidopa

DRUG

5-Hydroxytryptophan

50mg combined with 50mg carbidopa

DRUG

Carbidopa

50mg

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Wings for Life

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Jessica D'Amico, PhD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2026-06-30
Completion
2026-12-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04520178 on ClinicalTrials.gov